• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·7133.T
Share

HYUGA PRIMARY CARE Co.,Ltd. Stocks

¥ 2106Last Updated 16.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

¥ 94.88M

¥ 2106
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HYUGA PRIMARY CARE Co.,Ltd., established in 2007 and based in Kasuga, Japan, specializes in delivering a variety of primary care services, encompassing home-visit pharmacies, nursing support, and personalized care planning. The company extends its expertise to small and medium-sized pharmacy operators, equipping them with the necessary knowledge, technological systems, staffing solutions, and sales strategies to launch and manage their home visiting pharmacy operations. This includes providing their "Fam Care" home visit support information system, offering on-call system assistance, and guiding them in home palliative care. Furthermore, HYUGA PRIMARY CARE manages "Tai Support," an online platform that aids medical social workers in locating suitable senior housing options, such as assisted living facilities, private nursing homes, and group homes. The firm also develops the "Mimamori ICT Robot Terminal," a wearable device specifically designed for nursing care facilities. In addition to these services, it directly operates its own home visiting pharmacy, delivering prescription medications straight to patients' residences, and plays a significant role in the broader primary care home sector. The company changed its name from Hyuga Pharmacy Co., Ltd. to HYUGA PRIMARY CARE Co.,Ltd. in October 2020.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.10.2026 21:01

Anthropic's Valuation Falls, SpaceX Drives the Market: Key Takeaways on IPOs as of October 18

17.10.2026 21:12

DeepSeek unveils updated AI model claimed to be faster than its predecessor

17.10.2026 16:01

Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

‘All of this is going to pass’: Nvidia CEO is confident AI rally will continue

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026